NASDAQ:CNTB
Connect Biopharma Holdings Limited American Depositary Shares
- Stock
Last Close
1.36
26/07 20:00
Market Cap
68.88M
Beta: −0.54
Volume Today
20.54K
Avg: 344.89K
PE Ratio
−0.56
PFCF: −0.63
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|
average inventory | -21.98M - | |||||
average payables | 23.71M - | 52.92M 123.15% | 82.17M 55.28% | 45.40M 44.75% | ||
average receivables | 1.47M - | 24.49M 1,565.06% | 24.43M 0.24% | 896.50K 96.33% | ||
book value per share | -5.34 - | -19.00 255.55% | 33.21 274.76% | -57.76 273.95% | ||
capex per share | -0.02 - | -0.28 1,377.24% | -0.91 220.48% | -0.53 41.34% | ||
capex to depreciation | -1.36 - | -10.61 681.58% | -11.64 9.79% | -4.22 63.72% | -0.30 92.96% | |
capex to operating cash flow | 0.01 - | 0.09 670.82% | 0.09 4.73% | 0.04 50.54% | 0.01 85.78% | |
capex to revenue | ||||||
cash per share | 6.08 - | 18.97 211.75% | 32.65 72.15% | 19.31 40.86% | ||
days of inventory on hand | ||||||
days payables outstanding | ||||||
days sales outstanding | ||||||
debt to assets | 0.00 - | 0.00 64.45% | 0.00 49.22% | 0.00 478.87% | 0.00 49.31% | |
debt to equity | -0.00 - | -0.00 69.87% | 0.00 151.29% | -0.00 306.68% | 0.00 587.40% | |
dividend yield | 0.00 - | |||||
earnings yield | -0.02 - | -0.12 424.16% | -0.76 531.04% | -2.42 217.93% | ||
enterprise value | 6.88B - | 5.50B 20.13% | 9.32M 99.83% | -218.19M 2,441.39% | -105.54M 51.63% | |
enterprise value over ebitda | -40.28 - | -7.12 82.32% | -0.01 99.90% | 0.29 4,109.75% | ||
ev to operating cash flow | -76.24 - | -32.88 56.87% | -0.02 99.95% | 0.32 1,977.22% | 2.20 585.92% | |
ev to sales | ||||||
free cash flow per share | -1.64 - | -3.38 106.74% | -11.33 235.06% | -12.90 13.80% | ||
free cash flow yield | -0.01 - | -0.03 120.79% | -0.35 1,131.30% | -2.15 523.80% | ||
graham net net | -5.92 - | -20.12 239.96% | 31.04 254.26% | 17.24 44.46% | ||
graham number | 18.89 - | 78.89 317.73% | 136.67 73.23% | 137.28 0.44% | ||
income quality | 0.54 - | 0.21 59.92% | 0.42 94.63% | 0.85 104.75% | 0.81 5.59% | |
intangibles to total assets | 0 - | 0.00 Infinity% | 0.00 4.27% | 0.02 5,926.48% | 0.00 97.29% | |
interest coverage | -2.08K - | -4.71K 126.38% | -14.35K 204.78% | -5.59K 61.02% | ||
interest debt per share | 0.02 - | 0.02 5.69% | 0.02 9.56% | 0.06 256.97% | ||
inventory turnover | ||||||
invested capital | -0.00 - | -0.00 69.87% | 0.00 151.29% | -0.00 306.68% | 0.00 587.40% | |
market cap | 7.19B - | 6.51B 9.51% | 1.72B 73.63% | 329.08M 80.82% | ||
net current asset value | -308.06M - | -1.05B 241.82% | 1.63B 255.20% | 969.88M 40.66% | 96.12M 90.09% | |
net debt to ebitda | 1.80 - | 1.31 27.48% | 1.31 0.04% | 0.72 45.07% | ||
net income per share | -2.97 - | -14.56 390.79% | -25 71.72% | -14.50 42.00% | ||
operating cash flow per share | -1.62 - | -3.10 91.65% | -10.42 236.40% | -12.36 18.61% | ||
payables turnover | ||||||
receivables turnover | ||||||
research and ddevelopement to revenue | ||||||
return on tangible assets | -0.44 - | -0.72 62.95% | -0.70 2.72% | -0.67 4.91% | ||
revenue per share | ||||||
roe | 0.56 - | 0.77 38.03% | -0.75 198.26% | 0.25 133.34% | ||
roic | 0.37 - | 0.19 46.64% | -0.36 286.80% | 0.25 170.03% | ||
sales general and administrative to revenue | ||||||
shareholders equity per share | -5.34 - | -19.00 255.55% | 33.21 274.76% | -57.76 273.95% | ||
stock based compensation to revenue | ||||||
tangible asset value | -298.29M - | -1.03B 243.73% | 1.74B 269.25% | 1.07B 38.06% | 100.98M 90.60% | |
tangible book value per share | -5.34 - | -19.00 255.55% | 33.20 274.71% | 19.55 41.10% | ||
working capital | 335.42M - | 1.02B 203.74% | 1.64B 60.92% | 976.12M 40.46% | 96.71M 90.09% |
All numbers in USD (except ratios and percentages)